The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organization (WHO) has issued new guidelines recommending the twice-yearly use of injectable lenacapavir ...

We’ve come a long way in treating HIV, the virus that can lead to AIDs. Just last month, the FDA approved a medication that ...

Lenacapavir, which was approved by the United States' Food and Drug Administration in June this year, is taken twice per year ...

South Africa has accepted an offer of just over $29 million (about R520 million) from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir, that research ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...